Showing 1961-1970 of 3391 results for "".
New Products and Pharmacological Developments
https://practicaldermatology.com/columns/new-products/new-products-and-pharmacological-developments/20429/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20634/News
https://practicaldermatology.com/topics/practice-management/news/21202/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-29/23622/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20551/Medical Education and Technology: Intertwined like the Rod of Asclepius
https://practicaldermatology.com/columns/clinical-focus-1/medical-education-and-technology-intertwined-like-the-rod-of-asclepius/23453/Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
https://practicaldermatology.com/programs/cme/data-driving-preferred-guideline-recommendations-in-first-line-therapy-for-metastatic-melanoma/36327/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
https://practicaldermatology.com/programs/cme/data-driving-recent-guideline-updates-in-neoadjuvant-therapy-for-resectable-melanoma/36322/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.